Professional Documents
Culture Documents
Manufacturing Manufacturing
Manufacturing Manufacturing
PHARMA MANUFACTURING MARKETING PHARMA ASIA ANIMAL HEALTH DRUG DELIVERY VACCINES
Manufacturing
The market has witnessed several major trends that have governed the
evolution of contract manufacturing over the past few years. One of the most
signi cant changes in the outsourcing space is the emergence of strategic
contract manufacturing. The conventional model of contract manufacturing
involved a vendor-customer equation. However, phasing out that traditional
concept, contract manufacturers nowadays believe in entering in strategic
alliances with CMO partners with the objective of cutting down production
cost and enhancing product pipelines.
The report assesses some of the key drivers that have governed the evolution
of contract manufacturing market over the past several years along with an
elaborate discussion on the future trends that will shape the market in the
coming years. One of the focus areas of this study is to estimate size of the
future opportunity in the pharmaceutical contract manufacturing market over
the next decade, segmented on the basis of business operations and key
regions.
The base year for the report is 2014; the report provides market forecasts for
the period 2015 - 2025. The research, analysis and insights presented in this
Highlights
- North America and Europe are the predominant regions where majority of
the production facilities of CMOs are located. Out of 509 CMOs we studied,
189 have presence in multiple locations in the US. In Europe, the other major
hub for CMOs, Germany, Italy and the UK have presence of 58, 37 and 32
CMOs respectively. Companies have also gradually moved their focus to
developing countries in order to take advantage of the relatively lower costs.
- The market is well distributed between API manufacturers and FDF
manufacturers. Within FDF contract manufacturing, solid dose compounds
currently dominate the market. However, future growth is likely to be driven by
injectables dose manufacturing primarily due to increased focus on complex
disease areas and the growing trend of self-administration.
- In terms of analysis by scale of operation, majority of the CMOs have the
capability to operate on clinical as well as commercial scale. Out of 394 CMOs
evaluated for this exercise, 340 CMOs have the provision for both clinical and
commercial stage manufacturing.
- High potency and biopharmaceuticals manufacturing represent a major
growth opportunity for CMOs. Owing to the capital intensive nature of the
business and complex manufacturing requirements, CMOs have become the
preferred manufacturing partners for majority of the pharmaceutical clients.
- The intense competition in the marketplace is driving CMOs to explore
innovation aspects such as eClinical systems, cloud based computing and risk
monitoring tools to create di erentiation. Speci cally, for biopharmaceuticals
manufacturing, CMOs have started utilizing novel bio-processing services and
technologies such as single use bioreactors.
- With respect to the market size, we have estimated the API and FDF contract
manufacturing to be worth USD 35 Billion currently. Driven by the increasing
trend of outsourcing, we expect the market to grow at an annualized rate of
8.3%.
1. Preface
2. Executive Summary
3. Introduction
4. Market Overview
6. Competitive Landscape
12. Conclusion
Sector: Pharmaceuticals
Read more on
by Taboola
3 Foods To Avoid in 2017 46 States: Big Tobacco Must Pay These Former Celebrities Ended Up
BIO X4 Supplement Money Morning Working 9 To 5 Like The Rest Of Us
DailyDisclosure
Popular Content
Home Subscri be Ma na ge Newsl etter Subscri pti ons A dverti se Pri va cy Our Tea m C onta ct
2017 Questex LLC. All rights reserved.
275 Grove Street, Suite 2-130 Newton, MA 02466
Reproduction in whole or part is prohibited.